🔗 Share this article

While the United States proceeds with unprecedented revisions to its immunization schedules, an unexpected name has surfaced unexpectedly: Høeg, an American of Danish descent physician and public health researcher who rose to prominence by expressing skepticism about COVID-19 vaccines in the global health crisis and has focused upon possible deaths following COVID-19 vaccination in her recent tenure at the US Food and Drug Administration (FDA).

Planned Shifts to Pediatric Immunization Schedule

Health officials had intended to announce sweeping revisions to the childhood vaccine schedule in December, bringing the US with Denmark’s national calendar, according to reports – a substantial departure that would place the US at odds with much of the world with little proof for public health gain. The planned update has been postponed until the next year.

In place of Vinay Prasad, Dr. Høeg is scheduled to address the audience at the event. She was recently named interim head of the FDA’s CDER, the fifth person to head the division this calendar year.

A Shift at the Regulatory Body

This interim role may indicate a strengthened alliance between the pharmaceutical and vaccine divisions as Dr. Høeg and Prasad strengthen their influence at the FDA – and it suggests a greater focus upon dismantling already-approved vaccines at the FDA.

Høeg has frequently advocated for ending certain childhood immunization guidelines in the US to become more like the Danish model, a country with universal health coverage and a number of inhabitants roughly the size of the state of Wisconsin.

To date public appearances, she has continued to focus on immunizations – usually the domain of Dr. Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – rather than pharmaceutical oversight.

Doubts Over Expertise

Høeg has little discernible background in drug development, regulation or management, which has been typical for previous leaders of the biologics center. She has served at the FDA as a senior adviser to the agency head and CBER since spring.

“It seems she lacks to have the requisite experience” for overseeing the pharmaceutical oversight division, stated a neurologist and psychiatrist. “She’s never run a clinical trial. She has no expertise in leading a major agency. She lacks background in industry regulation.”

Previous directors of the center would “understand laws and regulations and the research of pharmaceutical innovation”, commented a former acting FDA commissioner. “Clearly, she has not acquired the sort of resume that former directors who ran CBER have had.”

CDER has an immense range of responsibilities at the agency, Woodcock emphasized.

“Everybody just pays attention on the novel medication approvals, but the generic drug division clears thousands of generic drugs. There’s a biosimilars division, OTC medication office and other areas, and every single one need to be supervised,” Dr. Woodcock noted. “The area you overlook, that is the part that I always told people is going to come back to haunt you.”

Additionally, a major administrative component to the position, which manages over 5,000 employees. “It is a massive management job, if you perform it correctly,” Woodcock concluded.

Official Statement and Controversial Initiatives

In response to questions about Dr. Høeg's credentials and whether this appointment signifies greater collaboration among FDA leaders on vaccines, a representative responded that the “inquiries rely on flawed premises”.

“This background matches the functions of her position,” the representative said, pointing to the months Dr. Høeg spent guiding the agency head on “drug safety and regulatory science, including predictive safety algorithms and immunization monitoring”.

In her interim role, Dr. Høeg assumes responsibility for the commissioner’s new expedited review system, a contentious expedited medication authorization process that reportedly troubled her former heads. “By what process are these medications being picked for this voucher program? Who makes the choices?” Howard questioned. “There’s a lot of lack of transparency occurring at the agency right now.”

In general, he remarked, “the agency appears to be shifting towards less stringent regulations of pharmaceuticals, with the exception of vaccines.”

Established History on Vaccines

Regarding vaccines, Dr. Høeg has a more established, if problematic, track record, critics have noted. She published a analysis using unconfirmed volunteer-provided data to assess the rate of myocarditis following Covid vaccination. She consulted for the Florida surgeon general Joseph Ladapo, who allegedly have changed statistics to imply COVID-19 vaccines are riskier than they are.

Included in her “policy goals” for the new federal leadership featured altering rules for recently developed shots and ending “unnecessary” vaccines, she said post-election on a online show. At the FDA, Høeg has reportedly floated the idea of barring teenage boys from receiving COVID-19 vaccinations.

“She is an complete true believer who commences with her preconceived notions and reverse-engineers to retrofit the evidence in a highly deceptive, fraudulent fashion,” Dr. Howard stated.

Taking Control and a “Push for Payback”

Høeg aligned with fellow contrarians, {like|